François Bocquet

Dr. François Bocquet

University of Nantes, Law and Social Change Laboratory, CNRS UMR 6297, France
+1

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Health Policy
Verified
Journal Article
Open access
François BocquetFrançois Bocquet
François Bocquet
ADAlbane Degrassat-Théas
Albane Degrassat-Théas
JPJérôme Peigné
Jérôme Peigné
PPPascal Paubel
Pascal Paubel
Drug shortages are becoming worrying for public health in the European Union. The French public authorities first took action against the causes of drug shortages in 2011 with a law, followed by a decree in 2012 to overcome the dysfunctions of the pharmaceutical distribution channel. These texts would establish emergency call centres implemented by pharmaceutical companies for pharmacists and for wholesalers to inform of shortages, and would oblige pharmaceutical companies to inform health authorities of any risk of potential shortage situation; they would also reinforce the declaration regime of the territory served by wholesalers. Through the Health Law of January 2016, France acquired new regulatory tools in order to fight against these shortages and wanted to target the drugs for which they are the most detrimental: the major therapeutic interest (MTI) drugs. Furthermore, this new text reinforces the legal obligations of pharmaceutical companies and of wholesalers for drug shortages and sets out the enforcement of sanctions in case of breach of these obligations. France's goal is ambitious: to implement coercive measures aiming at making the actors of the drug distribution channel aware of their responsibilities in order to take up the public health challenge triggered by drug shortages.

5 September 2014 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
François BocquetFrançois Bocquet
François Bocquet
PPPascal Paubel
Pascal Paubel
IFIsabelle Fusier
Isabelle Fusier
ACAnne-Laure Cordonnier
Anne-Laure Cordonnier
MSMartine Sinègre
Martine Sinègre
CPClaude Le Pen
Claude Le Pen

13 July 2016 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
François BocquetFrançois Bocquet
François Bocquet
ALAnaïs Loubière
Anaïs Loubière
IFIsabelle Fusier
Isabelle Fusier
ACAnne-Laure Cordonnier
Anne-Laure Cordonnier
PPPascal Paubel
Pascal Paubel

APAntoine PERPOIL
Antoine PERPOIL
GGGael GRIMANDI
Gael GRIMANDI
SBStéphane BIRKLE
Stéphane BIRKLE
JSJean-François SIMONET
Jean-François SIMONET
ACAnne CHIFFOLEAU
Anne CHIFFOLEAU
François BocquetFrançois Bocquet
François Bocquet
Biologic reference drugs and their copies, biosimilars, have a complex structure. Biosimilars need to demonstrate their biosimilarity during development but unpredictable variations can remain, such as micro-heterogeneity. The healthcare community may raise questions regarding the clinical outcomes induced by this micro-heterogeneity. Indeed, unwanted immune reactions may be induced for numerous reasons, including product variations. However, it is challenging to assess these unwanted immune reactions because of the multiplicity of causes and potential delays before any reaction. Moreover, safety assessments as part of preclinical studies and clinical trials may be of limited value with respect to immunogenicity assessments because they are performed on a standardised population during a limited period. Real-life data could therefore supplement the assessments of clinical trials by including data on the real-life use of biosimilars, such as switches. Furthermore, real-life data also include any economic incentives to prescribe or use biosimilars. This article raises the question of relevance of automating real life data processing regarding Biosimilars. The objective is to initiate a discussion about different approaches involving Machine Learning. So, the discussion is established regarding implementation of Neural Network model to ensure safety of biosimilars subject to economic incentives. Nevertheless, the application of Machine Learning in the healthcare field raises ethical, legal and technical issues that require further discussion.

29 April 2016 in Journal of Medical Economics
Verified
Journal Article
Open access
François BocquetFrançois Bocquet
François Bocquet
PPPascal Paubel
Pascal Paubel
(2016). First monoclonal antibody biosimilars: tackling the challenge of substitution. Journal of Medical Economics: Vol. 19, No. 6, pp. 645-647.